May 25, 2020 | Uncategorised
Hereditary Amyloidosis Canada (HAC) is pleased to learn that Akcea Therapeutics and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully completed negotiations for Tegsedi™ (inotersen) by signing a Letter of Intent (LOI) on April 30, 2020. Tegsedi is...
Feb 26, 2020 | Uncategorised
One year ago, we launched Hereditary Amyloidosis Canada (HAC) because we saw a need for a dedicated community, support group and information and resources for people living with hATTR amyloidosis. Since then, much has changed in the way hATTR amyloidosis is managed in...
